Here, although we focused on the impact of PBRM1 E27 AS on patients with ccRCC treated with nivolumab, we also uncovered the diverse frequency of E27 inclusion rates in PBRM1 transcripts in individual TCGA cancer tissues; these changes also vary between different cancer types. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.